A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty.

Trial Profile

A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2013

At a glance

  • Drugs Darexaban; Warfarin
  • Indications Thromboembolism
  • Focus Therapeutic Use
  • Acronyms PEARL
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 26 May 2010 Actual patient number (21) added as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 May 2009 Additional location (Canada) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top